N
Nanoform
Provides expert services in nanotechnology and drug particle engineering for the international pharma industry
About Nanoform
Nanoform is a pioneering company in the field of nanotechnology and drug particle engineering, specializing in the creation of nanoparticles for the pharmaceutical industry. The company operates in the global healthcare market, serving pharmaceutical companies looking to enhance the effectiveness and targeting of their drugs. Nanoform's core business model revolves around its multi-patented Controlled Expansion of Supercritical Solutions (CESS) technology, which can produce pure and stable nanoparticles as small as 10 nanometers using supercritical carbon dioxide. This technology significantly increases the number of lead compounds progressing into clinical trials, thereby boosting the number of drugs that reach the market. Nanoform generates revenue by providing nanoforming services to its clients, helping them overcome drug development challenges and rapidly progress novel drugs to market. The company has received multiple accolades, including the CPhI Excellence in Pharma Award for Formulation and a Seal of Excellence from the European Commission.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2015
- Headquarters
- Helsinki, Finland
- Listing
- IPO 2020
- Employees
- 122
- Open positions
- 1
- Dealroom signal
- 59.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Molecular, Spinout, Biotech and Pharma, Nordic Rising Star 2022, Top 50 Nordic Rising Star 2022 Finland, Hard Tech, Woman Founder, DT and LS, science-based
- Technology
- Nanotech
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Jun 2025 | $5.5M | — | Business Finland | ↗ |
| GRANT✓Other financing | Feb 2024 | $4.7M | — | Business Finland | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Nanoform is 7.7K monthly website visits, down 40.8% over the last three months. Nanoform's team declined 24.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Bill & Melinda Gates Foundation
Business Finland
Series A2 investors entered at this stage
Mandatum Life Insurance
Ilmarinen
Other known investors1 additional known investor
University of Helsinki
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nanoform on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nanoform’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.